Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,706 JPY
Change Today -5.00 / -0.29%
Volume 358.9K
4536 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 9:12 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

santen pharmaceutical co ltd (4536) Snapshot

Open
¥1,706
Previous Close
¥1,711
Day High
¥1,717
Day Low
¥1,694
52 Week High
05/22/15 - ¥1,892
52 Week Low
07/11/14 - ¥1,144
Market Cap
705.2B
Average Volume 10 Days
1.5M
EPS TTM
¥54.63
Shares Outstanding
413.4M
EX-Date
09/28/15
P/E TM
31.2x
Dividend
¥24.00
Dividend Yield
1.29%
Current Stock Chart for SANTEN PHARMACEUTICAL CO LTD (4536)

Related News

No related news articles were found.

santen pharmaceutical co ltd (4536) Related Businessweek News

No Related Businessweek News Found

santen pharmaceutical co ltd (4536) Details

Santen Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and marketing of ophthalmic and anti-rheumatic pharmaceuticals for the protection and enhancement of eyesight and health. The company offers various prescription pharmaceuticals in the areas, such as corneal and conjunctival epithelial disorders; glaucoma and ocular hypertension; retinal and uveal disorders; ocular infections/allergy; and rheumatoid arthritis. It also provides over-the-counter pharmaceuticals; and medical devices, such as foldable intraocular lenses. In addition, the company involved in cleaning antidust and sterilized clothing; and selling supplements, as well as marketing support for pharmaceuticals. Santen Pharmaceutical Co., Ltd. offers its products in Japan, rest of Asia, Europe, North America, and internationally. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Founded in 1890

santen pharmaceutical co ltd (4536) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: ¥90.0M
Compensation as of Fiscal Year 2015.

santen pharmaceutical co ltd (4536) Key Developments

TRACON Pharmaceuticals Announces IND Filing of DE-122 (TRC105) for Treatment of Wet Age-Related Macular Degeneration by Santen Pharmaceutical

TRACON Pharmaceuticals announced that its partner, Santen Pharmaceutical Co. Ltd. filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for the initiation of clinical studies for DE-122 in patients with wet AMD. DE-122 is the ophthalmic formulation of TRACON's proprietary anti-endoglin antibody, TRC105. In March 2014, Santen licenced the global rights for the development of TRC105 in ophthalmology from Tracon. Under the terms of the agreement, the IND filing for DE-122 triggers a $3 million milestone payment to TRACON.

Santen Pharmaceutical Co. Ltd. Launches COSOPT Mini Combination Ophthalmic Solution

Santen Pharmaceutical Co. Ltd. has launched COSOPT Mini Combination ophthalmic solution, indicated for the treatment of glaucoma and ocular hypertension, in Japan. Generic name of COSOPT Mini is dorzolamide hydrochloride/timolol maleate. COSOPT Mini is a preservative-free solution in single-dose sterile disposable vial. COSOPT Mini has the same active ingredients as COSOPT Combination ophthalmic solution which contains TRUSOPT ophthalmic solution 1% (generic name: dorzolamide hydrochloride), a carbonic anhydrase inhibitor, and TIMOPTOL ophthalmic solution 0.5% (generic name: timolol maleate), a beta-adrenergic receptor blocker agent.

Santen Pharmaceutical Co. Ltd. Announces Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the First Half Ending September 30, 2015 and Year Ending March 31, 2016

Santen Pharmaceutical Co. Ltd. announced consolidated earnings results for the year ended March 31, 2015. For the year, the company reported profit before tax was JPY 35.86 billion compared to JPY 30.36 billion for the year ended March 31, 2014. For the first half ending September 30, 2015 and full year ending March 31, 2015. For the first half, the company expects profit attributable to owners of the parent company to be JPY 41.5 billion and earnings per basic share to be JPY 100.42. Revenue to be JPY 92.5 billion, operating profit to be JPY 62 billion and profit before tax to be JPY 62.5 billion. For the fiscal year ending March 31, 2016, the company expects profit before tax to be JPY 78.5 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4536:JP ¥1,706.00 JPY -5.00

4536 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $42.54 USD -0.92
Almirall SA €17.15 EUR -0.49
Ironwood Pharmaceuticals Inc $12.20 USD +0.05
Nektar Therapeutics $11.68 USD -0.11
Synergy Health PLC 1,725 GBp +5.00
View Industry Companies
 

Industry Analysis

4536

Industry Average

Valuation 4536 Industry Range
Price/Earnings 28.9x
Price/Sales 4.3x
Price/Book 3.3x
Price/Cash Flow 24.7x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTEN PHARMACEUTICAL CO LTD, please visit www.santen.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.